SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine
SHL Telemedicine (NASDAQ: SHLT, SIX: SHLTN) has appointed David Arnon as its new CEO, effective August 6, 2024. Arnon, with over 17 years of experience in the healthcare insurance industry, will succeed Erez Nachtomy. He brings extensive expertise in sales, marketing, and operations, particularly in the Israeli healthcare sector.
Arnon's previous roles include CEO of DORAL MEA, Deputy CEO at Clal Insurance and Finance, and various executive positions at Harel Insurance Investments. The appointment aims to leverage his leadership skills to drive innovation, expand offerings, and strengthen SHL's global market presence in telemedicine solutions.
SHL Telemedicine (NASDAQ: SHLT, SIX: SHLTN) ha nominato David Arnon nuovo CEO, a partire dal 6 agosto 2024. Arnon, con oltre 17 anni di esperienza nel settore delle assicurazioni sanitarie, succederà a Erez Nachtomy. Porta con sé una vasta esperienza in vendite, marketing e operazioni, in particolare nel settore sanitario israeliano.
Le precedenti cariche di Arnon includono CEO di DORAL MEA, Vice CEO presso Clal Insurance and Finance, e vari ruoli dirigenziali presso Harel Insurance Investments. La nomina mira a sfruttare le sue capacità di leadership per promuovere l'innovazione, ampliare l'offerta e rafforzare la presenza globale di SHL nel mercato delle soluzioni di telemedicina.
SHL Telemedicine (NASDAQ: SHLT, SIX: SHLTN) ha nombrado a David Arnon como su nuevo CEO, efectivo desde el 6 de agosto de 2024. Arnon, con más de 17 años de experiencia en la industria de seguros de salud, sucederá a Erez Nachtomy. Aporta una amplia experiencia en ventas, marketing y operaciones, especialmente en el sector de la salud israelí.
Los cargos anteriores de Arnon incluyen CEO de DORAL MEA, Vice CEO en Clal Insurance and Finance, y diversas posiciones ejecutivas en Harel Insurance Investments. El nombramiento busca aprovechar sus habilidades de liderazgo para impulsar la innovación, ampliar la oferta y fortalecer la presencia global de SHL en soluciones de telemedicina.
SHL Telemedicine (NASDAQ: SHLT, SIX: SHLTN)은 David Arnon을 새로운 CEO로 임명했습니다, 2024년 8월 6일부터 유효합니다. Arnon은 17년 이상의 의료 보험 산업 경험을 보유하고 있으며, Erez Nachtomy의 후임자가 됩니다. 그는 판매, 마케팅 및 운영 분야에서 광범위한 전문 지식을 보유하고 있으며, 특히 이스라엘 의료 분야에서 두각을 나타내고 있습니다.
Arnon의 이전 직책으로는 DORAL MEA의 CEO, Clal Insurance and Finance의 부CEO, 그리고 Harel Insurance Investments의 여러 임원직이 있습니다. 이번 임명은 그의 리더십 능력을 활용하여 혁신을 촉진하고, 제공 범위를 확장하며, SHL의 글로벌 시장 존재감을 강화하는 것을 목표로 하고 있습니다.
SHL Telemedicine (NASDAQ: SHLT, SIX: SHLTN) a nommé David Arnon comme son nouveau PDG, effectif à partir du 6 août 2024. Arnon, avec plus de 17 ans d'expérience dans le secteur des assurances santé, succédera à Erez Nachtomy. Il apporte une expertise considérable en ventes, marketing et opérations, notamment dans le secteur de la santé en Israël.
Les postes précédents d'Arnon incluent PDG de DORAL MEA, Directeur Général Adjoints chez Clal Insurance and Finance, et divers postes de direction chez Harel Insurance Investments. La nomination vise à tirer parti de ses compétences en leadership pour stimuler l'innovation, élargir l'offre et renforcer la présence mondiale de SHL dans les solutions de télémédecine.
SHL Telemedicine (NASDAQ: SHLT, SIX: SHLTN) hat David Arnon als neuen CEO ernannt, der am 6. August 2024 sein Amt antreten wird. Arnon bringt über 17 Jahre Erfahrung in der Gesundheitsversicherungsbranche mit und wird Erez Nachtomy nachfolgen. Er hat umfassende Kenntnisse in Vertrieb, Marketing und Betrieb, insbesondere im israelischen Gesundheitssektor.
Arnon hatte zuvor Positionen als CEO von DORAL MEA, stellvertretender CEO bei Clal Insurance and Finance sowie verschiedene Führungspositionen bei Harel Insurance Investments inne. Die Ernennung zielt darauf ab, seine Führungskompetenzen zu nutzen, um Innovation voranzutreiben, das Angebot zu erweitern und die globale Marktpräsenz von SHL im Bereich der Telemedizinlösungen zu stärken.
- Appointment of experienced healthcare industry executive as new CEO
- New CEO brings extensive expertise in sales, marketing, and operations
- Potential for improved innovation and market expansion under new leadership
- None.
David Arnon held senior leadership and CEO roles within the healthcare insurance industry at Harel Insurance and Clal Insurance, two of the largest insurance groups in
TEL AVIV & ZURICH &
Mr. Arnon has over 17 years of commercial and executive level management experience within the healthcare insurance industry in
Yariv Alroy, Chairman of SHL said: “The Board welcomes David as our new CEO and looks forward to working closely with him. He is a proven leader of large, high growth organizations, has extensive operational and planning expertise, and an excellent understanding of customer management in general and in the healthcare field in particular. We would also like to thank Erez Nachtomy for successfully leading SHL during the last four years through a challenging period. We are sincerely grateful for his service and leadership.”
David Arnon commented: “I am honored to join SHL Telemedicine, a pioneer in telemedicine solutions. This is an exciting time for the Company as we continue to innovate and expand our offerings in the rapidly evolving healthcare landscape. I look forward to working with the talented team at SHL to drive our vision forward, enhance patient care through cutting-edge technology, and strengthen our market presence globally. Together, we will build on the Company’s leaderships and aim for new heights in delivering exceptional telemedicine services.”
David Arnon joins SHL from Doral Group (TASE:DORL), a prominent company in renewable energy, where he served as CEO of DORAL MEA. From 2018 to 2022, he was the Deputy CEO and Head of the Health Division and Customer Strategy at Clal Insurance and Finance, a subsidiary of Clal Insurance Enterprises Holdings (TASE:CLIS), one of
The Company will be publishing an invitation to a Special General Meeting of the Shareholders for approval of Mr. Arnon’s employment agreement and terms of compensation.
About SHL Telemedicine
SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200).
For more information, please visit our website at www.shl-telemedicine.com.
Forward-Looking Statements
Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240728163877/en/
Fabienne Farner, IRF, Phone: +41 43 244 81 42, farner@irf-reputation.ch
Source: SHL Telemedicine Ltd.
FAQ
Who is the new CEO of SHL Telemedicine (SHLT)?
What is David Arnon's background before joining SHL Telemedicine (SHLT)?
When will David Arnon assume the role of CEO at SHL Telemedicine (SHLT)?
Who is David Arnon replacing as CEO of SHL Telemedicine (SHLT)?
